Pharmaceuticals & Biotech German Community

Item 1 – Business (what the company does) �Johnson & Johnson is a New Jersey–incorporated healthcare holding company with operating subsidiaries in virtually all countries and ~138,200 employees focused on human health and well‑being. �Operates in two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices and technologies).Read more

Perspectivas de Mercado Olhando para o horizonte de 2026 e além, a Bayer AG emerge como uma empresa em transição estratégica, navegando por desafios persistentes enquanto aposta em inovação e eficiência operacional para impulsionar uma recuperação sustentável. Após um 2025 marcado por declínios em lucros e pressões litigiosas, a companhia projeta um retorno ao crescimento de lucros a partir de 2026, impulsionado por um pipeline robusto em farmacêuticos, otimizações em Crop Science e uma reestruturação interna que visa economias significativas.Read more

Ecco cosa dicono gli utili di Novo Nordisk del Q4 2024 Nonostante le azioni si trovino ai minimi degli ultimi 15 mesi e il sentiment generale sia un po' ribassista, i dati del Q4 offrono spunti interessanti. Il colosso farmaceutico europeo ha registrato un incremento del 30,1% nelle vendite , raggiungendo 11,48 miliardi EUR, superando così le attese.Read more

SCHOTT Pharma sells packaging and delivery parts for injectable medicines, but tougher climate rules, trade barriers, and cheaper rivals could squeeze its profits and slow its growth. At the same time, changes in how medicines are taken and where drugmakers want to source supplies may reshape which markets it can win next.Read more

Formycon could get a near-term boost from regulators easing development work and from pushing its biosimilar medicines into new regions, including a more user-friendly injection option in Europe. But shifting U.S. pricing, possible legal delays, and higher project costs could still slow sales and put pressure on results.Read more

Bayer’s newer medicines and push into climate-friendly farming are gaining traction faster than many expect, hinting that the business could rebound sooner than the market is pricing in. But big legal battles, tougher rules, and heavy debt could still keep a lid on how far the recovery can go.Read more

Evotec is caught in a squeeze: its customers are spending more cautiously, regulators are moving slower, and rising costs plus tougher competition could make it harder to protect profits. The story also has a twist—moves toward a leaner business and new data-driven partnerships could still set up a rebound if the transition goes smoothly.Read more

Merck KGaA is leaning harder into areas that can bring steadier repeat business, from bioprocessing supplies to cancer medicines and advanced materials used in electronics. The upside case depends on new drug launches and a rebound in chip-related demand, while drug patent cliffs, regulation, and cost pressure could quickly change the story.Read more

SCHOTT Pharma is betting big on newer packaging that helps drugmakers deliver injectable medicines more safely and conveniently, and it’s building extra production capacity to meet demand. The upside comes from deeper partnerships and more sustainable materials, but weak demand for some older products, high spending, and leadership turnover could still derail the story.Read more